Medtronic PLC (NYSE:MDT) Receives $102.14 Consensus Price Target from Brokerages

Medtronic PLC (NYSE:MDT) has been given a consensus rating of “Moderate Buy” by the nineteen research firms that are presently covering the company, MarketBeat.com reports. Eight research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $102.1429.

Several equities research analysts have weighed in on MDT shares. Royal Bank Of Canada dropped their price target on shares of Medtronic from $105.00 to $101.00 and set an “outperform” rating for the company in a research report on Thursday, May 22nd. Leerink Partners started coverage on shares of Medtronic in a research report on Monday, June 16th. They issued an “outperform” rating and a $110.00 target price for the company. Wall Street Zen raised shares of Medtronic from a “hold” rating to a “buy” rating in a research note on Saturday, August 30th. William Blair raised shares of Medtronic to a “hold” rating in a research note on Friday, July 11th. Finally, Citigroup lifted their target price on shares of Medtronic from $99.00 to $101.00 and gave the company a “buy” rating in a report on Thursday, August 21st.

Insider Activity at Medtronic

In other news, EVP Harry Skip Kiil sold 8,605 shares of Medtronic stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total transaction of $788,045.90. Following the completion of the transaction, the executive vice president directly owned 35,615 shares in the company, valued at approximately $3,261,621.70. This trade represents a 19.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director William R. Jellison bought 2,500 shares of the stock in a transaction dated Monday, August 25th. The shares were acquired at an average price of $92.37 per share, with a total value of $230,925.00. Following the completion of the acquisition, the director directly owned 5,000 shares of the company’s stock, valued at approximately $461,850. The trade was a 100.00% increase in their position. The disclosure for this purchase can be found here. 0.26% of the stock is currently owned by company insiders.

Institutional Trading of Medtronic

A number of large investors have recently made changes to their positions in the stock. Lavaca Capital LLC grew its stake in shares of Medtronic by 40.7% in the second quarter. Lavaca Capital LLC now owns 692 shares of the medical technology company’s stock worth $60,000 after acquiring an additional 200 shares during the period. Cypress Capital Advisors LLC grew its position in Medtronic by 56.2% in the 2nd quarter. Cypress Capital Advisors LLC now owns 10,897 shares of the medical technology company’s stock worth $950,000 after purchasing an additional 3,919 shares during the period. Orion Porfolio Solutions LLC grew its position in Medtronic by 4.2% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 94,876 shares of the medical technology company’s stock worth $8,270,000 after purchasing an additional 3,856 shares during the period. MASTERINVEST Kapitalanlage GmbH bought a new stake in Medtronic in the 2nd quarter worth approximately $1,302,000. Finally, Cim Investment Management Inc. grew its position in Medtronic by 99.6% in the 2nd quarter. Cim Investment Management Inc. now owns 15,675 shares of the medical technology company’s stock worth $1,309,000 after purchasing an additional 7,822 shares during the period. 82.06% of the stock is currently owned by institutional investors.

Medtronic Price Performance

Shares of Medtronic stock opened at $94.04 on Friday. Medtronic has a 52-week low of $79.29 and a 52-week high of $96.25. The stock has a market capitalization of $120.62 billion, a price-to-earnings ratio of 25.91, a price-to-earnings-growth ratio of 2.36 and a beta of 0.77. The company has a fifty day moving average of $91.19 and a 200-day moving average of $88.20. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.50 and a current ratio of 2.01.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.23 by $0.03. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The company had revenue of $8.58 billion during the quarter, compared to analysts’ expectations of $8.37 billion. During the same quarter in the prior year, the company earned $1.23 EPS. The firm’s revenue was up 7.7% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. Equities research analysts expect that Medtronic will post 5.46 EPS for the current year.

Medtronic Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 17th. Stockholders of record on Friday, September 26th will be issued a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 3.0%. The ex-dividend date is Friday, September 26th. Medtronic’s dividend payout ratio (DPR) is presently 78.24%.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.